Ucbbiopharma Srl

Sanofi

Tracy Lynn Arakaki

John Robert Porter

Daniel John Lightwood

Alastair Lawson

James Philip O'Connell

Rebecca Jayne Munro

Graham John Warrellow

Stephen Edward Rapecki

Boris Kroeplien

Timothy John Norman

Mark Daniel Calmiano

William Ross Pitt

Alex Buntin Burgin

David Andreas Schubert

Rebecca Jayne Wootton

James Philip O'CONNELL

It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.

Methods of use of anti-TNFα antibodies

A new, stable trimeric TNF&#x3b1; structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNF&#x3b1;/TNFR1 interaction. Membrane-bound TNF&#x3b1; is not affected in its ability to signal through TNFR2, and thus the new structure of TNF&#x3b1; may be used in therapies which do not significantly raise the risk of infection or malignancy.

Method of identifying potential inhibitors of APO TNF&#x3b1; trimers

Antibodies binding to trimeric TNF alpha epitopes

Treatment of autoimmune and inflammatory disorders with asymmetric TNF alpha trimers

Growing community of inventors

Slough, United Kingdom

Tracy Lynn Arakaki